アジア太平洋地域の抗ウイルス薬市場 – 業界動向と2030年までの予測

Customize Your Report レポートをカスタマイズする Buy Now 今すぐ購入 Free Sample Report 無料サンプルレポート
Home Pharmaceutical アジア太平洋地域の抗ウイルス薬市場
Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

アジア太平洋地域の抗ウイルス薬市場 – 業界動向と2030年までの予測

  • Pharmaceutical
  • Published Report
  • May 2023
  • Asia-Pacific
  • 350 ページ
  • テーブル数: 654
  • 図の数: 45
Buy Now 今すぐ購入

アジア太平洋地域の抗ウイルス薬市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
 2024 –2030
Diagram 市場規模（基準年）
 USD MILLION
Request
Diagram Market Size (Forecast Year)
 USD 15,118.64
Diagram CAGR
 %
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

>アジア太平洋地域の抗ウイルス薬市場、適応症別（インフルエンザ、ヒト免疫不全ウイルス（HIV）、C型肝炎ウイルス（HCV）、RSウイルス、単純ヘルペスウイルス、ヒトサイトメガロウイルス（HCMV）、水痘帯状疱疹ウイルス（VZV）、B型肝炎ウイルス（HBV）、コロナウイルス感染症、その他）、患者タイプ別（小児、成人、高齢者）、製品別（経口、局所、非経口）、薬剤タイプ別（ジェネリック、ブランド）、エンドユーザー別（病院、診療所、在宅医療、専門センター、外来センター、その他）、流通チャネル別（病院薬局、オンライン薬局、小売薬局） - 2030年までの業界動向と予測。  

アジア太平洋地域の抗ウイルス薬市場

アジア太平洋地域の抗ウイルス薬市場の分析と洞察

アジア太平洋地域でのウイルス感染に関する意識の高まりにより、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げと承認に重点を置いています。さらに、医薬品開発技術の進歩の向上も、抗ウイルス薬の需要増加に貢献しています。

アジア太平洋地域の抗ウイルス薬市場アジア太平洋地域の抗ウイルス薬市場

アジア太平洋地域の抗ウイルス薬市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長すると予想されています。これに伴い、メーカーは市場で新しいサービスを開始するための開発活動に取り組んでいます。医薬品開発分野の開発の増加は、市場の成長をさらに後押ししています。ただし、標準化されたプロトコルの欠如や熟練した専門家の不足などの困難が、予測期間中のアジア太平洋地域の抗ウイルス薬市場の成長を妨げる可能性があります。

医療費の進歩と医薬品開発への支出の増加は、市場にチャンスをもたらすと予想されます。しかし、代替治療の使用の増加は市場の成長を阻害する可能性があります。データブリッジマーケットリサーチは、アジア太平洋地域の抗ウイルス薬市場は、予測期間中に6.7％のCAGRで成長し、2030年までに151億1,864万米ドルに達すると予測しています。  

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2015～2020年にカスタマイズ可能)

定量単位

売上高は百万ドル、販売数量はユニット数、価格は米ドル

対象セグメント

適応症（インフルエンザ、ヒト免疫不全ウイルス（HIV）、C型肝炎ウイルス（HCV）、RSウイルス、単純ヘルペスウイルス、ヒトサイトメガロウイルス（HCMV）、水痘帯状疱疹ウイルス（VZV）、B型肝炎ウイルス（HBV）、コロナウイルス感染症、その他）、患者タイプ（小児、成人、高齢者）、製品（経口、局所、非経口）、薬剤タイプ（ジェネリックおよびブランド）、エンドユーザー（病院、診療所、在宅医療、専門センター、外来センター、その他）、流通チャネル（病院薬局、オンライン薬局、小売薬局）

対象国

中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他アジア太平洋地域

対象となる市場プレーヤー

Gilead Sciences, Inc.、F. Hoffmann-La Roche Ltd、GLAXOSMITHKLINE PLC、Abbvie、Merck & Co., Inc.、Johnson & Johnson Services, Inc.、Bristol-Myers Squibb Company、Cipla Inc.、Aurobindo Pharma、Dr. Reddy's Laboratories Ltd.、Zydus Pharmaceuticals, Inc.、Mylan Pharmaceuticals ULC、Teva Pharmaceuticals USA, Inc.、EMERGENT、Sun Pharmaceutical Industries Ltd.、Avet Pharmaceuticals Inc.、Pfizer Inc.、SIGA Technologies、NAVINTA LLC.、Macleods Pharmaceuticals Ltd.、BioCryst Pharmaceuticals, Inc、Hetero など

アジア太平洋地域の抗ウイルス薬市場の定義

抗ウイルス薬は、宿主細胞内でのウイルスの複製を阻害することでウイルス感染症を治療するために使用される薬剤です。これらの薬は特定のウイルスまたはウイルスの種類をターゲットとし、ウイルスが宿主細胞に侵入するのを防ぐか、ウイルスの複製に必要な主要な酵素またはタンパク質を阻害することで作用します。細菌感染症の治療に使用される抗生物質とは異なり、抗ウイルス薬はウイルスの構造がはるかに単純で、複製には宿主細胞に依存するため、一般的に効果は低くなります。ただし、インフルエンザ、ヘルペス、HIVなどの一部のウイルス感染症の治療には依然として有効です。

アジア太平洋地域の抗ウイルス薬市場の動向

このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。     

ドライバー

  • ウイルス感染の蔓延

過去数十年間、ウイルス感染は世界中で着実に増加しています。体内に侵入し、その細胞を利用して複製し、拡散するウイルスは、ウイルス感染を引き起こします。ウイルス感染は、軽度から重度までさまざまな症状を引き起こし、場合によっては命にかかわることもあります。グローバル化は、ウイルス感染増加の主な原因の 1 つです。人々は国境を越えて旅行し、互いにコミュニケーションを取り、世界はかつてないほどつながっています。このつながりの強化により、ある地域から別の地域へのウイルスの伝染が加速しています。

このように、ウイルス感染の蔓延の増加は、多くの要因が絡み合った複雑な問題です。グローバル化、人口密度、気候変動、抗生物質耐性はすべて、ウイルスの蔓延に影響を与えます。そのため、市場の成長を促進することが期待されています。

  • 新しい抗ウイルス薬開発の進歩

抗ウイルス治療は、ウイルス感染患者に処方されます。新しい抗ウイルス薬の開発は、時を経て大きな進歩を遂げてきました。これらの開発により、疾病負担が軽減され、ウイルス感染の治療が改善され、命が救われました。新しい抗ウイルス薬の分野では、多くの開発が行われています。

このように、新しい抗ウイルス薬開発の進歩により、ウイルス感染症の治療が改善され、疾病負担が軽減され、市場の成長を促進することが期待されています。

拘束

  • 抗ウイルス薬の高コスト

抗ウイルス薬の高額な費用は、患者と医療制度に重大な影響を及ぼす可能性があります。これらの薬を買う余裕のない患者は、治療を受けられなかったり、質の低い治療に頼ったりして、健康状態が悪化する可能性があります。さらに、抗ウイルス薬の高額な費用は、特に資源が限られている国では、医療予算を圧迫する可能性があります。

したがって、抗ウイルス薬の高コストは、アジア太平洋地域の抗ウイルス薬市場を抑制すると予想されます。

機会

  • 新たな薬物送達システムの台頭

抗ウイルス薬の研究では、新しい薬物送達メカニズムの開発に重点が置かれてきました。従来の薬物投与技術と比較して、新しい送達システムには、生物学的利用能の向上、カスタマイズされた薬物送達、副作用の減少など、いくつかの利点があります。

したがって、新しい薬物送達システムの開発は、抗ウイルス薬の重要な研究分野です。ナノ粒子薬物送達システム、ハイドロゲル、デンドリマー、マイクロニードル、細胞浸透ペプチドは、抗ウイルス薬のために研究されてきた有望な薬物送達システムの一部です。これらの送達システムは、従来の薬物送達方法に比べていくつかの利点があり、抗ウイルス薬の有効性と安全性を向上させる可能性があり、市場の成長の機会を生み出すことが期待されています。

チャレンジ

  • 抗ウイルス薬の特許切れ

特許の失効により、元の開発者または特許所有者は特定の医薬品を製造および販売する独占権を失います。抗ウイルス薬の特許失効は、ジェネリック医薬品の製造業者との競争を招く可能性があるため、製薬業界に大きな影響を与える可能性があります。

抗ウイルス薬の特許は、その作成者がその薬を製造し販売する独占権を持つ期間の終了時に失効します。薬の特許の失効後、他の製造者がジェネリック版を作成し販売することができます。これにより、競争が激化し、消費者価格が下がる可能性があります。HIV、B型肝炎、C型肝炎、ヘルペス、インフルエンザ、その他のウイルス性疾患はすべて抗ウイルス薬で治療されます。抗ウイルス薬の特許の失効時期は、薬と国によって異なります。薬の特許は通常、申請日から20年間付与されます。特許の失効後、他の製造者は自由にジェネリック版の薬を作成し販売することができます。製造者はマーケティング、研究開発、臨床研究にそれほど費用をかける必要がないため、ジェネリック医薬品はブランド薬よりも手頃な価格であることが多いです。

したがって、抗ウイルス薬の特許切れは、これらの重要な医薬品の入手可能性、手頃な価格、およびアクセス性に大きな影響を与える可能性があり、市場の成長に対する課題となることが予想されます。

最近の動向

  • 2023年1月、MSDとして知られるメルクは、子会社を通じて、Imago Biosciences, Inc.（Nasdaq: IMGO）の発行済み普通株式のすべてに対する現金公開買付けが成功したと発表しました。購入価格は1株あたり36.00米ドルの現金で、利息なしで、必要な源泉徴収税の控除の対象となります。この買収は収益の成長に貢献します。
  • 2021年4月、ザイダス・ファーマシューティカルズ社は、中等度のCOVID-19感染症の治療に抗ウイルス薬ビラフィンを使用するため、インド医薬品管理総局（DCGI）から限定的な緊急使用許可を受けたと発表しました。これにより、同社はアジア太平洋地域での存在感を高め、世界の他の地域での評判を高めることができるでしょう。

アジア太平洋地域の抗ウイルス薬市場の範囲

アジア太平洋地域の抗ウイルス薬市場は、適応症、患者タイプ、製品、薬剤タイプ、エンドユーザー、流通チャネルに基づいて、6 つの主要なセグメントに分割されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コア アプリケーション領域とターゲット市場の違いを判断するのに役立ちます。    

表示

  • インフルエンザ
  • ヒト免疫不全ウイルス（HIV）
  • C型肝炎ウイルス
  • 単純ヘルペスウイルス
  • ヒトサイトメガロウイルス (HCMV)
  • 水痘帯状疱疹ウイルス (VZV)
  • B型肝炎ウイルス
  • RSウイルス
  • コロナウイルス 感染
  • その他

アジア太平洋地域の抗ウイルス薬市場は、適応症に基づいて、インフルエンザ、ヒト免疫不全ウイルス（HIV）、C型肝炎ウイルス（HCV）、RSウイルス、単純ヘルペスウイルス、ヒトサイトメガロウイルス（HCMV）、水痘帯状疱疹ウイルス（VZV）、B型肝炎ウイルス（HBV）、コロナウイルス感染症などに分類されています。

患者タイプ

  • 子供
  • アダルト
  • 老年病

患者タイプに基づいて、アジア太平洋地域の抗ウイルス薬市場は、小児、成人、高齢者に分類されます。  

製品

  • オーラル
  • 話題
  • 非経口

製品に基づいて、アジア太平洋地域の抗ウイルス薬市場は、経口、局所、非経口に分類されます。

薬剤の種類

  • ジェネリック
  • ブランド

薬剤の種類に基づいて、アジア太平洋地域の抗ウイルス薬市場はジェネリックとブランドに分類されます。

エンドユーザー

  • 病院
  • クリニック
  • 在宅医療
  • 専門センター
  • 外来センター
  • その他

エンドユーザーに基づいて、アジア太平洋地域の抗ウイルス薬市場は、病院、診療所、在宅医療、専門センター、外来センター、その他に分類されます。

流通チャネル

  • 病院薬局
  • オンライン薬局
  • 小売薬局

流通チャネルに基づいて、アジア太平洋地域の抗ウイルス薬市場は、病院薬局、オンライン薬局、小売薬局に分類されます。

抗ウイルス薬市場

アジア太平洋地域の抗ウイルス薬市場の地域分析/洞察

アジア太平洋地域の抗ウイルス薬市場は、適応症、患者タイプ、製品、薬剤タイプ、エンドユーザー、流通チャネルに基づいて、6 つの主要なセグメントに分類されています。

この市場レポートで取り上げられている国は、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、およびその他のアジア太平洋諸国です。

2023年には、主要企業の強力な存在と新興市場からの需要の増加と拡大により、日本がアジア太平洋地域を支配するでしょう。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境とアジア太平洋地域の抗ウイルス薬市場シェア分析

アジア太平洋地域の抗ウイルス薬市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、および製品タイプのライフライン曲線が含まれます。上記のデータ ポイントは、アジア太平洋地域の抗ウイルス薬市場への会社の重点にのみ関連しています。   

アジア太平洋地域の抗ウイルス薬市場で活動している主要企業には、Gilead Sciences、Inc.、F. Hoffmann-La Roche Ltd、GLAXOSMITHKLINE PLC、Abbvie、Merck & Co.、Inc.、Johnson & Johnson Services、Inc.、Bristol-Myers Squibb Company、Cipla Inc.、Aurobindo Pharma、Dr. Reddy's Laboratories Ltd.、Zydus Pharmaceuticals、Inc.、Mylan Pharmaceuticals ULC、Teva Pharmaceuticals USA、Inc.、EMERGENT、Sun Pharmaceutical Industries Ltd.、Avet Pharmaceuticals Inc.、Pfizer Inc.、SIGA Technologies、NAVINTA LLC.、Macleods Pharmaceuticals Ltd.、BioCryst Pharmaceuticals、Inc.、Hetero などがあります。

SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

Sample Image 画像をクリックすると拡大します
  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

7 REGULATORY FRAMEWORK

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS

8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT

8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES

8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES

8.2 RESTRAINS

8.2.1 HIGH COST OF ANTIVIRAL DRUGS

8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES

8.3 OPPORTUNITIES

8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS

8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS

8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES

8.4 CHALLENGES

8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS

8.4.2 DEMAND FOR ALTERNATIVE MEDICINES

9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION

9.1 OVERVIEW

9.2 INFLUENZA

9.2.1 NEURAMINIDASE INHIBITORS

9.2.1.1 OSELTAMIVIR

9.2.1.2 ZANAMIVIR

9.2.1.3 PERAMIVIR

9.2.1.4 LANINAMIVIR

9.2.2 M2 INHIBITORS

9.2.2.1 RIMANTADINE

9.2.2.2 OTHERS

9.2.3 RNA POLYMERASE INHIBITORS

9.2.3.1 FAVIPIRAVIR

9.2.3.2 BALOXAVIR MARBOXIL

9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)

9.3.1 REVERSE TRANSCRIPTASE INHIBITORS

9.3.1.1 NUCLEOSIDE (NRTIS)

9.3.1.1.1 LAMIVUDINE

9.3.1.1.2 ABACAVIR

9.3.1.1.3 DIDANOSINE

9.3.1.1.4 OTHERS

9.3.1.2 NONNUCLEOSIDE (NNRTIS)

9.3.1.2.1 EFAVIRENZ

9.3.1.2.2 NEVIRAPINE

9.3.1.2.3 DELAVIRDINE

9.3.1.2.4 OTHERS

 

9.3.1.3 INTEGRASE

9.3.1.3.1 DOLUTEGRAVIR

9.3.1.3.2 ELVITEGRAVIR

9.3.1.3.3 RALTEGRAVIR

9.3.1.3.4 BICTEGRAVIR

9.3.1.4 NUCLEOTIDE

9.3.1.4.1 TENOFOVIR

9.3.1.4.2 OTHERS

9.3.1.5 INTERFERONS

9.3.1.5.1 ALPHA

9.3.1.5.2 BETA

9.3.1.5.3 GAMMA

9.3.1.6 GP41

9.3.1.6.1 ENFUVIRTIDE

9.3.1.6.2 OTHERS

9.3.2 PROTEASE

9.3.2.1 ATAZANAVIR

9.3.2.2 DARUNAVIR

9.3.2.3 LOPINAVIR

9.3.2.4 RITONAVIR

9.3.2.5 SAQUINAVIR

9.3.2.6 INDINAVIR

9.3.2.7 NELFINAVIR

9.3.2.8 TIPRANAVIR

9.3.2.9 AMPRENAVIR

9.4 HEPATITIS C VIRUS

9.4.1 NS5B POLYMERASE

9.4.1.1 SOFOSBUVIR

9.4.1.2 DASABUVIR

9.4.2 NS3/4A PROTEASE

9.4.2.1 DANOPREVIR

9.4.2.2 GLECAPREVIR

9.4.2.3 GRAZOPREVIR

9.4.2.4 PARITAPREVIR

9.4.2.5 SIMEPREVIR

 

9.4.3 NS5A PHOSPHOPROTEIN

9.4.3.1 LEDIPASVIR

9.4.3.2 VELPATASVIR

9.4.3.3 OMBITASVIR

9.4.3.4 ELBASVIR

9.4.3.5 DACLATASVIR

9.4.3.6 PIBRENTASVIR

9.4.4 NEURAMINIDASE

9.4.4.1 OSELTAMIVIR

9.4.4.2 ZANAMIVIR

9.4.4.3 PERAMIVIR

9.4.4.4 LANINAMIVIR

9.4.5 RNA POLYMERASE

9.4.5.1 BALOXAVIR MARBOXIL

9.4.5.2 FAVIPIRAVIR

9.4.6 MATRIX PROTEIN 2

9.4.6.1 RIMATIDINE

9.4.6.2 FAVIPIRAVIR

9.5 HERPES SIMPLEX VIRUS

9.5.1 DNA POLYMERASE UL30

9.5.1.1 ACICLOVIR

9.5.1.2 FAMCICLOVIR

9.5.1.3 VALACICLOVIR

9.5.1.4 PENCICLOVIR TRIFLURIDINE

9.5.1.5 BRIVUDINE

9.5.1.6 FOSCARNET

9.5.1.7 IDOXURIDINE

9.5.2 ENVELOPE PROTEINS

9.5.2.1 DOCOSANOL

9.5.2.2 OTHERS

9.6 HUMAN CYTOMEGALOVIRUS (HCMV)

9.6.1 GANCICLOVIR

9.6.2 VALGANCICLOVIR

9.6.3 CIDOFOVIR

9.6.4 FOSCARNET

9.6.5 FOMIVIRSEN

 

9.7 VARICELLA-ZOSTER VIRUS (VZV)

9.7.1 VALACICLOVIR

9.7.2 FAMCICLOVIR

9.7.3 ACICLOVIR

9.7.4 VIDARABINE

9.7.5 BRIVUDINE

9.8 HEPATITIS B VIRUS

9.8.1 ENTECAVIR

9.8.2 TENOFOVIR

9.8.3 TELBIVUDINE

9.8.4 TENOFOVIR ALAFENAMIDE

9.8.5 OTHERS

9.9 RESPIRATORY SYNCYTIAL VIRUS

9.9.1 RNA POLYMERASE

9.9.1.1 RIBAVIRIN

9.9.1.2 OTHERS

9.9.2 FUSION GLYCOPROTEIN

9.9.2.1 PALIVIZUMAB

9.9.2.2 OTHERS

9.1 CORONAVIRUS INFECTION

9.11 OTHERS

10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 GERIATRIC

10.2.1 MALE

10.2.2 FEMALE

10.3 CHILD

10.3.1 MALE

10.3.2 FEMALE

10.4 ADULT

10.4.1 MALE

10.4.2 FEMALE

 

11 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS

11.1 OVERVIEW

11.2 ORAL

11.2.1 SOLID

11.2.1.1 TABLETS

11.2.1.2 CAPSULES

11.2.1.3 OTHERS

11.2.2 SEMISOLID

11.2.2.1 GELS

11.2.2.2 EMULSIONS

11.2.2.3 ELIXIRS

11.2.2.4 OTHERS

11.2.3 LIQUID

11.2.3.1 SOLUTIONS

11.2.3.2 SYRUPS

11.2.3.3 OTHERS

11.3 TOPICAL

11.3.1 SEMI-SOLID

11.3.1.1 CREAM

11.3.1.2 OINTMENT

11.3.1.3 GELS

11.3.1.4 OTHERS

11.3.2 LIQUID

11.3.2.1 SOLUTIONS

11.3.2.2 SUSPENSIONS

11.3.3 SOLID

11.3.3.1 POWDERS

11.3.3.2 SUPPOSITORIES

11.3.3.3 ENEMA

11.3.3.4 OTHERS

11.4 PARENTERAL

11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS

11.4.1.1 SOLUTIONS

11.4.1.2 RECONSTITUTED/LYOPHILIZED

11.4.1.3 SUSPENSIONS

11.4.1.4 EMULSIONS

11.4.1.5 OTHERS

11.4.2 NOVEL DRUG DELIVERY FORMULATIONS

11.4.3 COLLOIDAL DISPERSIONS

11.4.4 LONG ACTING INJECTION FORMULATION

12 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 SPECIALTY CENTERS

13.4 AMBULATORY CENTRES

13.5 CLINICS

13.6 HOME HEALTHCARE

13.7 OTHERS

14 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

15 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

 

18 COMPANY PROFILE

18.1 GILEAD SCIENCES, INC. (2022)

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 PFIZER INC. (2022)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 SIGA TECHNOLOGIES (2022)

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 GLAXOSMITHKLINE PLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 F. HOFFMANN-LA ROCHE LTD. (2022)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBVIE INC.

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

 

18.7 AUROBINDO PHARMA (2022)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AVET PHARMACEUTICALS INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 BRISTOLL MYERS SQUIBB (2022)

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 BIOCRYST PHARMACEUTICALS, INC. (2022)

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 CIPLA INC. (2022)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 DR. REDDY’S LABORATORIES LTD. (2022)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 EMERGENT (2022)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 HETERO.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

 

18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MACLEODS PHARMACEUTICALS LTD.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MERCK & CO., INC, (2022)

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022)

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 NAVINTA LLC.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.21.1 COMPANY SNAPSHOT

18.21.2 REVENUE ANALYSIS

18.21.3 PRODUCT PORTFOLIO

18.21.4 RECENT DEVELOPMENT

18.22 ZYDUS PHARMACEUTICALS, INC. (2022)

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENTS

 

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 2 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 5 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 16 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 17 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 19 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 22 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 23 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 24 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 25 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 63 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 90 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 91 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 92 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 93 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 94 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 95 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 96 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 97 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 98 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 99 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 100 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 101 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 102 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 103 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 104 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 105 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 106 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 107 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 108 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 109 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 110 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 111 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 112 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 113 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 114 JAPAN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 115 JAPAN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 116 JAPAN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 117 JAPAN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 118 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 JAPAN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 120 JAPAN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 121 JAPAN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 122 JAPAN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 123 JAPAN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 124 JAPAN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 125 JAPAN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 126 JAPAN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 127 JAPAN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 128 JAPAN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 129 JAPAN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 130 JAPAN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 131 JAPAN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 132 JAPAN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 133 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 134 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 135 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 136 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 137 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 138 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 139 JAPAN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 140 JAPAN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 141 JAPAN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 142 JAPAN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 143 JAPAN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 144 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 145 JAPAN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 146 JAPAN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 147 JAPAN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 148 JAPAN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 149 JAPAN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 150 JAPAN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 151 JAPAN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 152 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 153 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 154 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 155 JAPAN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 156 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 157 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 158 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 159 JAPAN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 160 JAPAN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 161 JAPAN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 162 JAPAN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 163 JAPAN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 164 JAPAN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 165 CHINA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 166 CHINA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 167 CHINA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 168 CHINA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 169 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 170 CHINA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 171 CHINA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 172 CHINA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 173 CHINA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 174 CHINA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 175 CHINA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 176 CHINA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 177 CHINA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 178 CHINA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 179 CHINA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 CHINA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 181 CHINA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 182 CHINA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 183 CHINA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 184 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 185 CHINA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 186 CHINA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 187 CHINA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 188 CHINA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 189 CHINA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 190 CHINA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 191 CHINA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 192 CHINA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 193 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 194 CHINA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 195 CHINA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 196 CHINA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 197 CHINA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 198 CHINA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 199 CHINA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 200 CHINA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 201 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 202 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 203 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 204 CHINA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 205 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 206 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 207 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 208 CHINA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 209 CHINA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 210 CHINA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 211 CHINA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 212 CHINA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 CHINA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 215 SOUTH KOREA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 216 SOUTH KOREA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 217 SOUTH KOREA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 218 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 219 SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 220 SOUTH KOREA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 221 SOUTH KOREA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 222 SOUTH KOREA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 223 SOUTH KOREA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 224 SOUTH KOREA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 225 SOUTH KOREA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 226 SOUTH KOREA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 227 SOUTH KOREA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 228 SOUTH KOREA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 229 SOUTH KOREA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 230 SOUTH KOREA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 231 SOUTH KOREA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 232 SOUTH KOREA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 233 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 234 SOUTH KOREA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 235 SOUTH KOREA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 236 SOUTH KOREA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 237 SOUTH KOREA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 238 SOUTH KOREA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 239 SOUTH KOREA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 240 SOUTH KOREA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 241 SOUTH KOREA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 242 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 243 SOUTH KOREA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 244 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 245 SOUTH KOREA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 246 SOUTH KOREA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 247 SOUTH KOREA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 248 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 249 SOUTH KOREA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 250 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 251 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 252 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 253 SOUTH KOREA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 254 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 255 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 256 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 257 SOUTH KOREA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 258 SOUTH KOREA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 259 SOUTH KOREA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 260 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 261 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 262 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 263 INDIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 264 INDIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 265 INDIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 266 INDIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 267 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 268 INDIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 269 INDIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 270 INDIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 271 INDIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 272 INDIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 273 INDIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 274 INDIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 275 INDIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 276 INDIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 277 INDIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 278 INDIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 279 INDIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 280 INDIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 281 INDIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 282 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 283 INDIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 284 INDIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 285 INDIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 286 INDIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 287 INDIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 288 INDIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 289 INDIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 290 INDIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 291 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 292 INDIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 293 INDIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 294 INDIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 295 INDIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 296 INDIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 297 INDIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 298 INDIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 299 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 300 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 301 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 302 INDIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 303 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 304 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 305 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 306 INDIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 307 INDIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 308 INDIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 309 INDIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 310 INDIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 311 INDIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 312 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 313 AUSTRALIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 314 AUSTRALIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 315 AUSTRALIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 316 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 317 AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 318 AUSTRALIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 319 AUSTRALIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 320 AUSTRALIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 321 AUSTRALIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 322 AUSTRALIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 323 AUSTRALIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 324 AUSTRALIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 325 AUSTRALIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 326 AUSTRALIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 327 AUSTRALIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 328 AUSTRALIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 329 AUSTRALIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 330 AUSTRALIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 331 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 332 AUSTRALIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 333 AUSTRALIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 334 AUSTRALIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 335 AUSTRALIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 336 AUSTRALIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 337 AUSTRALIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 338 AUSTRALIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 339 AUSTRALIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 340 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 341 AUSTRALIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 342 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 343 AUSTRALIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 344 AUSTRALIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 345 AUSTRALIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 346 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 347 AUSTRALIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 348 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 349 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 350 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 351 AUSTRALIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 352 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 353 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 354 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 355 AUSTRALIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 356 AUSTRALIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 357 AUSTRALIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 358 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 359 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 360 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 361 SINGAPORE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 362 SINGAPORE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 363 SINGAPORE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 364 SINGAPORE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 365 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 366 SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 367 SINGAPORE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 368 SINGAPORE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 369 SINGAPORE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 370 SINGAPORE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 371 SINGAPORE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 372 SINGAPORE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 373 SINGAPORE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 374 SINGAPORE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 375 SINGAPORE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 376 SINGAPORE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 377 SINGAPORE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 378 SINGAPORE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 379 SINGAPORE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 380 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 381 SINGAPORE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 382 SINGAPORE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 383 SINGAPORE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 384 SINGAPORE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 385 SINGAPORE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 386 SINGAPORE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 387 SINGAPORE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 388 SINGAPORE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 389 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 390 SINGAPORE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 391 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 392 SINGAPORE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 393 SINGAPORE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 394 SINGAPORE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 395 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 396 SINGAPORE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 397 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 398 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 399 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 400 SINGAPORE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 401 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 402 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 403 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 404 SINGAPORE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 405 SINGAPORE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 406 SINGAPORE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 407 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 408 SINGAPORE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 409 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 410 THAILAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 411 THAILAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 412 THAILAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 413 THAILAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 414 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 415 THAILAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 416 THAILAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 417 THAILAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 418 THAILAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 419 THAILAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 420 THAILAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 421 THAILAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 422 THAILAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 423 THAILAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 424 THAILAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 425 THAILAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 426 THAILAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 427 THAILAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 428 THAILAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 429 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 430 THAILAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 431 THAILAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 432 THAILAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 433 THAILAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 434 THAILAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 435 THAILAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 436 THAILAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 437 THAILAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 438 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 439 THAILAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 440 THAILAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 441 THAILAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 442 THAILAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 443 THAILAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 444 THAILAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 445 THAILAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 446 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 447 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 448 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 449 THAILAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 450 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 451 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 452 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 453 THAILAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 454 THAILAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 455 THAILAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 456 THAILAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 457 THAILAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 458 THAILAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 459 MALAYSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 460 MALAYSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 461 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 462 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 463 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 464 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 465 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 466 MALAYSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 467 MALAYSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 468 MALAYSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 469 MALAYSIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 470 MALAYSIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 471 MALAYSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 472 MALAYSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 473 MALAYSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 474 MALAYSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 475 MALAYSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 476 MALAYSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 477 MALAYSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 478 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 479 MALAYSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 480 MALAYSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 481 MALAYSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 482 MALAYSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 483 MALAYSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 484 MALAYSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 485 MALAYSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 486 MALAYSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 487 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 488 MALAYSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 489 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 490 MALAYSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 491 MALAYSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 492 MALAYSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 493 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 494 MALAYSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 495 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 496 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 497 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 498 MALAYSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 499 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 500 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 501 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 502 MALAYSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 503 MALAYSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 504 MALAYSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 505 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 506 MALAYSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 507 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 508 INDONESIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 509 INDONESIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 510 INDONESIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 511 INDONESIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 512 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 513 INDONESIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 514 INDONESIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 515 INDONESIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 516 INDONESIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 517 INDONESIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 518 INDONESIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 519 INDONESIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 520 INDONESIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 521 INDONESIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 522 INDONESIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 523 INDONESIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 524 INDONESIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 525 INDONESIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 526 INDONESIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 527 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 528 INDONESIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 529 INDONESIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 530 INDONESIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 531 INDONESIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 532 INDONESIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 533 INDONESIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 534 INDONESIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 535 INDONESIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 536 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 537 INDONESIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 538 INDONESIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 539 INDONESIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 540 INDONESIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 541 INDONESIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 542 INDONESIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 543 INDONESIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 544 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 545 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 546 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 547 INDONESIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 548 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 549 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 550 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 551 INDONESIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 552 INDONESIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 553 INDONESIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 554 INDONESIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 555 INDONESIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 556 INDONESIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 557 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 558 PHILIPPINES INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 559 PHILIPPINES NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 560 PHILIPPINES M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 561 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 562 PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 563 PHILIPPINES REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 564 PHILIPPINES NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 565 PHILIPPINES INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 566 PHILIPPINES NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 567 PHILIPPINES INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 568 PHILIPPINES GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 569 PHILIPPINES PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 570 PHILIPPINES HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 571 PHILIPPINES NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 572 PHILIPPINES NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 573 PHILIPPINES NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 574 PHILIPPINES NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 575 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 576 PHILIPPINES MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 577 PHILIPPINES HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 578 PHILIPPINES DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 579 PHILIPPINES ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 580 PHILIPPINES HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 581 PHILIPPINES VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 582 PHILIPPINES DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 583 PHILIPPINES RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 584 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 585 PHILIPPINES FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 586 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 587 PHILIPPINES GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 588 PHILIPPINES CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 589 PHILIPPINES ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 590 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 591 PHILIPPINES ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 592 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 593 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 594 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 595 PHILIPPINES TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 596 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 597 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 598 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 599 PHILIPPINES PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 600 PHILIPPINES CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 601 PHILIPPINES NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 602 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 603 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 604 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 605 VIETNAM ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 606 VIETNAM INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 607 VIETNAM NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 608 VIETNAM M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 609 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 610 VIETNAM HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 611 VIETNAM REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 612 VIETNAM NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 613 VIETNAM NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 614 VIETNAM INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 615 VIETNAM NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 616 VIETNAM INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 617 VIETNAM GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 618 VIETNAM PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 619 VIETNAM HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 620 VIETNAM NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 621 VIETNAM NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 622 VIETNAM NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 623 VIETNAM NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 624 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 625 VIETNAM MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 626 VIETNAM HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 627 VIETNAM DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 628 VIETNAM ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 629 VIETNAM HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 630 VIETNAM VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 631 VIETNAM DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 632 VIETNAM RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 633 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 634 VIETNAM FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 635 VIETNAM ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 636 VIETNAM GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 637 VIETNAM CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 638 VIETNAM ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 639 VIETNAM ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 640 VIETNAM ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 641 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 642 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 643 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 644 VIETNAM TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 645 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 646 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 647 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 648 VIETNAM PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 649 VIETNAM CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 650 VIETNAM NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 651 VIETNAM ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 652 VIETNAM ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 653 VIETNAM ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 654 REST OF ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 ASIA-PACIFIC ANTIVIRAL DRUGS: SEGMENTATION

FIGURE 2 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF VIRAL INFECTIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 12 THE INFLUENZA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET IN 2023 & 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

FIGURE 16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , 2022

FIGURE 17 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , 2023-2030 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , CAGR (2023-2030)

FIGURE 19 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY INDICATION , LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2022

FIGURE 21 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)

FIGURE 22 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, CAGR (2023-2030)

FIGURE 23 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2022

FIGURE 25 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 26 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 27 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2022

FIGURE 29 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)

FIGURE 30 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 31 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, 2022

FIGURE 33 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 34 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 35 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 36 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 37 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 38 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 39 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: SNAPSHOT (2022)

FIGURE 41 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022)

FIGURE 42 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 43 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 44 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: INDICATION (2023-2030)

FIGURE 45 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Asia-Pacific antiviral drugs market size will be worth USD 15,118.64 million by 2030.
The growth rate of the Asia-Pacific antiviral drugs market is 6.7% in the forecast period by the year 2030.
Rising prevalence of viral infections & Advancements in new antiviral drug development are the growth drivers of the Asia-Pacific antiviral drugs market.
Indication, patient type, products, drug type, end user, and distribution channel are the factors on which the Asia-Pacific antiviral drugs market research is based.
Major companies in the Asia-Pacific antiviral drugs market are Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, and Hetero. among others.

関連ページを閲覧する

Banner